Short Interest in Certara, Inc. (NASDAQ:CERT) Decreases By 7.5%

Certara, Inc. (NASDAQ:CERT) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 4,960,000 shares, a decline of 7.5% from the October 31st total of 5,360,000 shares. Approximately 4.5% of the shares of the stock are short sold. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 3.8 days.

Insider Activity

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. bought a new position in shares of Certara during the second quarter worth about $26,000. Innealta Capital LLC acquired a new stake in shares of Certara in the second quarter valued at approximately $36,000. KBC Group NV lifted its position in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Intech Investment Management LLC acquired a new position in Certara during the second quarter worth $152,000. Finally, Algert Global LLC bought a new position in Certara in the second quarter valued at $156,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Down 2.7 %

Shares of NASDAQ CERT traded down $0.30 during midday trading on Wednesday, reaching $10.96. 924,798 shares of the stock were exchanged, compared to its average volume of 808,562. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The business has a 50-day simple moving average of $10.82 and a two-hundred day simple moving average of $12.94. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -56.30, a P/E/G ratio of 5.71 and a beta of 1.53.

Certara (NASDAQ:CERT) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period last year, the company posted $0.06 EPS. As a group, equities research analysts expect that Certara will post 0.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CERT shares. Robert W. Baird decreased their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th. Finally, Barclays reduced their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Certara presently has an average rating of “Hold” and a consensus price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.